Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

Roche app allows access to latest cancer guidelines

Roche has launched an app allowing access to the latest guidelines covering the most common forms of cancer.

Roche sets analysts purring with strong Q3 results

Roche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines faring better than expected against cheaper biosimilar rivals.

Roche backs Rituxan with further data in rare skin disease P...

Roche’s Rituxan (rituximab) has been on the market for years as a blood cancer drug, and is finally succumbing to pressure from cut-price biosimilars.

Humira tops list of drugs with unwarranted US price hikes

NICE says 'no' to regular NHS funding for Roche's Tecentriq ...

NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it